SCHEDULE 13G: BlackRock Discloses 5.1% Stake in LifeCore Biomedical
Beneficial Ownership Report
BlackRock, Inc. has reported a 5.1% beneficial ownership stake in LifeCore Biomedical, Inc., holding 1,899,903 shares of common stock.
Summary
- BlackRock, Inc. has filed a Schedule 13G, disclosing its beneficial ownership in LIFECORE BIOMEDICAL, INC.
- As of December 31, 2025, BlackRock beneficially owned an aggregate of 1,899,903 shares of LIFECORE BIOMEDICAL, INC. Common Stock.
- This ownership represents 5.1% of the total outstanding shares of the class.
- BlackRock holds sole voting power over 1,876,400 shares and sole dispositive power over 1,899,903 shares.
- No shared voting or dispositive power was reported.
- The filing indicates that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 7
Explanation: The filing indicates a significant institutional investment by BlackRock, which is generally a positive signal of confidence in the company's value and prospects, without any negative disclosures.
Positives
- Significant institutional investment from BlackRock, a major global asset manager, signals confidence in LifeCore Biomedical, Inc.
Risks
- The filing itself does not detail risks related to the issuer's operations or financial health, as it is an ownership disclosure.
Future Outlook
NA
Industry Context
The disclosure of a significant stake by a major institutional investor like BlackRock can be viewed positively within the biotechnology and medical device industry, often indicating a belief in the company's long-term prospects or strategic position.
Comparison to Industry Standards
- Institutional ownership by firms like BlackRock is common across publicly traded companies, particularly in established sectors like biomedical. A 5.1% stake is a notable position for a single institutional investor.
Stakeholder Impact
- Shareholders: Increased institutional ownership may lend credibility and stability to the stock, potentially attracting further investment.
- Management: A significant institutional holder like BlackRock may exert influence through voting power, aligning with long-term strategic goals.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney date, which was revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. attorneys-in-fact. |
| 2025-12-31 | Date of event requiring the filing of this statement, reflecting beneficial ownership as of this date. |
| 2026-01-21 | Date the Schedule 13G was signed and filed by BlackRock, Inc. |
Keywords
BlackRock, LifeCore Biomedical, LCTX, Beneficial Ownership, Institutional Investor, Schedule 13G, Common Stock, Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.